Newland Pharmaceutical (301277.SZ) has obtained the approval notification for the listing application of chlorpheniramine maleate API.

Newland Pharmaceutical (301277.SZ) announced on February 24, 2025, that the company has received the approval letter for the sale of raw materials for chlorpheniramine maleate issued by the National Medical Products Administration. Chlorpheniramine maleate is an antihistamine drug that can reduce the permeability of capillaries, inhibit histamine, and is mainly used to treat allergic rhinitis, allergic skin mucosa, and control drug rash and contact dermatitis. The approval for the sale of raw materials for chlorpheniramine maleate obtained by the company indicates that the raw material meets the relevant Chinese drug evaluation technical standards and has been approved for use in domestic formulations. This will further enrich the company's product range.